Disease Prevention & Control Summit

Debiopharm, a Swiss-based biopharmaceutical company, develops, manufactures, and invests in innovative therapies and technologies that respond to high unmet medical needs in oncology and bacterial infections.

Centrient Pharmaceuticals is the global leader in the production and commercialisation of sustainable antibiotics, next-generation statins and anti-fungals.

Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA.

Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems.

Abbott is a global healthcare leader that helps people live more fully at all stages of life.

With more than 25 years of molecular experience, BioFire Diagnostics, LLC (now bioMérieux) sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing.

Over a decade ago, Cepheid set the standard for innovation in automated molecular diagnostics with our first system and we’ve never looked back.

Innovation is complex. The journey from idea to market is not straightforward and requires a diverse range of know-how, investment, market knowledge and research.

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome.

The Menarini Group is the leading Italian pharmaceutical company in the world, a guarantee of internationally recognised quality.

Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases.

MicroGenDX specializes in low-cost, highly accurate qPCR + NGS microbial DNA diagnostics — providing answers where cultures or PCR alone have failed. More than 80,000 medical professionals have used MicroGenDx to run more than 1.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE:R9Q) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superb

We are the CRISPR and Gene Therapy of the Microbiome company! Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human mic

VectorB2B provide integrated services in drug discovery and screening, project design and implementation, pre-clinical contract research (efficacy and ADME), contract manufacturing and clinical trials management.

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections.

We are a biopharmaceutical company that aims to deliver innovative therapeutics to help people live better lives.